Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hydralazine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    10 result(s) found for: Hydralazine. Displaying page 1 of 1.
    EudraCT Number: 2019-003671-19 Sponsor Protocol Number: 71534 Start Date*: 2020-01-13
    Sponsor Name:Stichting Epilepsie Instellingen Nederland
    Full Title: Efficacy and safety of hydralazine in combination with valproate to treat hypocretin deficiency in recent onset narcolepsy: a pilot study
    Medical condition: Narcolepsy type 1
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10028713 Narcolepsy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004091-35 Sponsor Protocol Number: EMC-NET1 Start Date*: 2019-04-19
    Sponsor Name:Erasmus University Medical Center
    Full Title: Improving Treatment Options for Somatostatin Type 2 Receptor Negative Neuroendocrine Tumor Patients
    Medical condition: Neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077559 Gastroenteropancreatic neuroendocrine tumour disease PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10078174 Neuroendocrine tumour of the lung PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001143-70 Sponsor Protocol Number: SMD-Txago2010 Start Date*: 2011-06-30
    Sponsor Name:Breno Moreno de Gusmao
    Full Title: no
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    14.0 10005329 - Blood and lymphatic system disorders 10035227 Plasma cell neoplasms HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002209-38 Sponsor Protocol Number: 7418-503 Start Date*: 2008-10-17
    Sponsor Name:NovaCardia, Inc. (A wholly owned subsidiary of Merck & Co., Inc.)
    Full Title: A multicenter, randomized, double-blind, placebo-controlled study of the hemodynamic effects of rolofylline injectable emulsion in the treatment of patients with heart failure
    Medical condition: Patients hospitalised with heart failure, volume overload and renal impairment, who require loop diuretic therapy and hemodynamic monitoring for clinical reasons
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000803 Acute heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000414-20 Sponsor Protocol Number: CHANCE-HF Start Date*: 2011-08-02
    Sponsor Name:Consorcio de Apoyo a la Investigacion Biomedica en Red (CAIBER)
    Full Title: Ensayo aleatorizado controlado sobre la terapia guiada por el antígeno carbohidrato 125 en los pacientes dados de alta por insuficiencia cardiaca aguda: efecto sobre la mortalidad a 1 año.
    Medical condition: acute heart failure
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10007556 Cardiac failure acute PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004977-10 Sponsor Protocol Number: 08meInnereA_GALACTIC Start Date*: 2013-07-25
    Sponsor Name:University Hospital Basel, Cardiology
    Full Title: Goal-directed Afterload Reduction in Acute Congestive Cardiac Decompensation Study
    Medical condition: - acute decompensated heart failure
    Disease: Version SOC Term Classification Code Term Level
    19.0 10042613 - Surgical and medical procedures 10054112 Hospitalisation PT
    19.0 10018065 - General disorders and administration site conditions 10011906 Death PT
    19.0 10042613 - Surgical and medical procedures 10022519 Intensive care PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prohibited by CA) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-000490-40 Sponsor Protocol Number: S320.2.003 Start Date*: 2007-06-20
    Sponsor Name:Solvay Pharmaceuticals GmbH
    Full Title: Randomised, Double-Blind, Placebo-Controlled, Multi-Center, Sequential Cohort Study to Evaluate the Effect of SLV320 in Addition to Chronic Furosemide Treatment on Renal Function in Subjects with C...
    Medical condition: Renal Function in Subjects with Congestive Heart Failure and Impaired Renal Function who are on Chronic Furosemide Treatment
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010684 Congestive heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Prematurely Ended) ES (Ongoing) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-002181-38 Sponsor Protocol Number: WARCEF Start Date*: 2004-10-22
    Sponsor Name:NIH-National Institut of Health - NINDS-National Institut of Neurogical Disorders and Stroke
    Full Title: Warfarin versus Aspirin in Reduced Ejection Fraction.
    Medical condition: Patients with left ventricular disfunction with ejection fraction less or equal to 35%.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002545-32 Sponsor Protocol Number: CR0002 Start Date*: 2019-11-06
    Sponsor Name:Ablative Solutions, Inc
    Full Title: A Pivotal, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine System™ Kit, in Subjects with Hypertension.
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing) SE (Ongoing) BE (Ongoing) NL (Ongoing) IE (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000046-19 Sponsor Protocol Number: RIVAROXHFA3001/BAY59-7939/16302 Start Date*: 2013-08-23
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Oral Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Sub...
    Medical condition: Prevention of death, heart attack and stroke in patients with chronic heart failure and significant coronary artery disease following a hospitalization for exacerbation of heart failure.
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) DE (Completed) NL (Completed) BG (Completed) PL (Completed) HU (Completed) SE (Completed) IT (Completed) GB (Completed) EE (Completed) LT (Completed) PT (Completed) DK (Completed) LV (Completed) SK (Completed) GR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:06:18 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA